17722-32-6

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
2-CYANO-N-(2,4-DICHLORO-PHENYL)-ACETAMIDE is used as a research chemical for the development of new pharmaceuticals due to its unique structural features and potential pharmacological properties. Its cyano and 2,4-dichloro-phenyl groups may offer specific binding affinities or interactions with biological targets, making it a candidate for further exploration in medicinal chemistry.
Used in the Treatment of Various Diseases and Conditions:
While further research is required, 2-CYANO-N-(2,4-DICHLORO-PHENYL)-ACETAMIDE may have potential applications in the treatment of various diseases and conditions. Its specific use cases will depend on the outcomes of ongoing studies and clinical trials, which will determine its efficacy, safety, and appropriate therapeutic indications.

InChI:InChI=1/C9H6Cl2N2O/c10-6-1-2-8(7(11)5-6)13-9(14)3-4-12/h1-2,5H,3H2,(H,13,14)

Upstream product

• 554-00-7 2,4-Dichloroaniline 
• 372-09-8 cyanoacetic acid 

Downstream Products

• 102817-88-9 N-(2,4-Dichloro-phenyl)-2-thiocarbamoyl-acetamide 
• 62004-09-5 LFM-A₂₀ 
• 1032226-75-7 5-amino-N-(2,4-dichlorophenyl)-1-(2-methylphenyl)-1H-1,2,3-triazole-4-carboxamide 
• 102818-12-2 2-(2,4-Dichloro-phenyl)-4,6-dimethyl-isothiazolo[5,4-b]pyridin-3-one 
• 102818-19-9 2-(2,4-Dichloro-phenyl)-4,6-dimethyl-1-oxo-1,2-dihydro-1λ⁴-isothiazolo[5,4-b]pyridin-3-one 
• 102817-99-2 4,6-Dimethyl-2-thioxo-1,2-dihydro-pyridine-3-carboxylic acid (2,4-dichloro-phenyl)-amide 
• 929716-54-1 4-(2,4-dichloro-phenylamino)-7-iodo-6-methoxy-quinoline-3-carbonitrile 
• 929716-52-9 2-cyano-N-(2,4-dichloro-phenyl)-3-(3-iodo-4-methoxy-phenylamino)-acrylamide 

Relevant academic research and scientific papers

Discovery of a Small-Molecule Modulator of Glycosaminoglycan Sulfation

Glycosaminoglycans (GAGs) play critical roles in diverse processes ranging from viral infection to neuroregeneration. Their regiospecific sulfation patterns, which are generated by sulfotransferases, are key structural determinants that underlie their biological activity. Small-molecule modulators of these sulfotransferases could serve as powerful tools for understanding the physiological functions of GAGs, as well as potential therapeutic leads for human diseases. Here, we report the development of the first cell-permeable, small-molecule inhibitor selective for GAG sulfotransferases, which was obtained using a high-throughput screen targeted against Chst15, the sulfotransferase responsible for biosynthesis of chondroitin sulfate-E (CS-E). We demonstrate that the molecule specifically inhibits GAG sulfotransferases in vitro, decreases CS-E and overall sulfation levels on cell-surface and secreted chondroitin sulfate proteoglycans (CSPGs), and reverses CSPG-mediated inhibition of axonal growth. These studies pave the way toward a new set of pharmacological tools for interrogating GAG sulfation-dependent processes and may represent a novel therapeutic approach for neuroregeneration.

Inhibition of Src kinase activity by 7-ethynyl-4-phenylamino-3-quinolinecarbonitriles: Identification of SKS-927

Of a series of 7-ethynyl-3-quinolinecarbonitriles, the most potent Src inhibitory activity was observed with 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[4-(4-methylpiperazi n-1-yl)but-1-ynyl]-3-quinolinecarbonitrile (SKS-927). Variation of the so

Structural influence on the intermolecular/intramolecular hydrogen bonding in solid state of substituted leflunomides: Evidence by X-ray crystal structure

We report the results of an X-ray crystal structure study of nine substituted leflunomide metabolite analogs (LFM). Comparison of the hydrogen bonding characteristics exhibited by these structurally distinct LFM analogs was especially informative about the inter- and intra-molecular hydrogen bonding patterns that exist in the crystal structure of individual compounds. All compounds had the strong intramolecular hydrogen bonds. In addition, with the exception of the 2,5-difluorophenyl substituted LFM analog, all other compounds formed inter- or intra-molecular hydrogen bonds with the halogen atom and the NH group. However, we found that the presence of a fluorine atom at the 2-position on the phenyl ring of the 2,5-difluoro and 2-fluoro derivatives resulted in only one intramolecular hydrogen bond in the structural framework. Conversely, the 3,5-difluoro substituted LFM analog had an intramolecular hydrogen bond common to the other halide substituted derivatives. The anomaly exhibited by the 2,5-difluoro and the 2-fluoro substituted compounds may be owing to the smaller size of fluorine atom in comparison with the chlorine and bromine atoms in the structures of the other analogs. The presence of a fluorine at the 2-position of the phenyl ring may disrupt the intermolecular hydrogen bonding that was observed for the other derivatives due to differences in the crystal packing for these molecules.